Product Description
FRTX-10 inhibits STING palmitoylation, thereby inhibiting the activation of STING and resulting in an efficient shutdown of the STING downstream pathway. Upon in vivo stimulation of mice with a STING agonist, oral administration of FRTX-10 was observed to reduce serum cytokine levels of IL-6 and IFN-b. (Sourced from: https://www.frtx.com/pipeline/frtx-10/)
Mechanisms of Action: STING Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fresh Tracks Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Autoimmune Disease Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|